Stacy Coen

Mrs. Coen brings over 20 years of business and corporate development experience from leading oncology and rare disease companies. She is currently the Chief Business Officer for ImmunoGen, a company that is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. Prior to ImmunoGen, Mrs. Coen worked at Editas Medicine, where she served as Vice President, Business Development and was responsible for business development, strategy, transactions, and alliance management. While at Editas, Mrs. Coen worked on various transactions to enable company progress in the cell therapy field. Prior to joining Editas, Mrs. Coen served in multiple roles of increasing responsibility at Genzyme Corporation (now known as Sanofi Genzyme), including Vice President, Head of Rare Disease Business Development and Licensing, and Vice President, Global Head of Strategy and Business Development, Multiple Sclerosis, among others. She currently serves on the Board of Trustees of Huntington’s Disease Society of America and is a member of MassBio and the Alliance for Regenerative Medicine (ARM). Mrs. Coen received a BS in Finance and Economics from the University of Massachusetts and an MBA from the Darden Graduate School of Business at the University of Virginia.